Overview
- NHS England, which announced the rollout Sunday, has begun offering a ready-to-use pembrolizumab injection across services in England.
- The shot is given under the skin in one minute every three weeks or two minutes every six weeks depending on cancer type.
- Most of the roughly 14,000 people who start pembrolizumab each year in England are expected to move to the injection.
- MSD says the ready-to-administer format cuts staff preparation time by 44 percent, which could free more clinic slots.
- The medicine is the same PD-1 therapy and IV use stays in place for patients receiving other drip treatments.